Video
Dr. Kelly on the Next Steps With Radium-223 and Niraparib in mCRPC
Author(s):
William K. Kelly, DO, discusses the next steps with the combination of radium-223 dichloride and niraparib in metastatic castration-resistant prostate cancer.
William K. Kelly, DO, professor of medical oncology and urology, Thomas Jefferson University, and director of the Division of Solid Tumor Oncology at Sidney Kimmel Cancer Center, discusses the next steps with the combination of radium-223 dichloride (Xofigo) and niraparib (Zejula) in metastatic castration-resistant prostate cancer (mCRPC).
Results from a phase 1b dose-finding study (NCT03076203) showed reduced prostate-specific antigen and alkaline phosphatase levels with radium-223/niraparib in chemotherapy-naïve patients with mCRPC.
The trial evaluated an unselected patient population, explains Kelly.
A subgroup analysis of patients with DNA damage repair (DDR) alterations is being conducted to determine the efficacy of the combination in that subset of patients, says Kelly.
Additionally, an expanded phase 2 study is investigating the combination in chemotherapy-naïve patients who do not have DDR mutations, concludes Kelly.
